CTOs on the Move

PDS Biotechnology

www.pdsbiotech.com

 
PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body`s immune system in the fight against cancer and infectious disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pdsbiotech.com
  • 25B Vreeland Road Suite 300
    Florham Park, NJ USA 07932
  • Phone: 800.208.3343

Executives

Name Title Contact Details

Similar Companies

Agrivida

Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.

RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx`s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.

EMD Biosciences

EMD Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a San Carlos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Solutions

Advanced Solutions designs and manufactures biofabrication systems for next-generation drug discovery, personalized medicine, and regenerative therapeutics.